Kelsey Czekai, PA-C | |
369 Locust Street, First Floor, Columbia, PA 17512 | |
(717) 342-2577 | |
(717) 449-5082 |
Full Name | Kelsey Czekai |
---|---|
Gender | Female |
Speciality | Physician Assistant - Medical |
Location | 369 Locust Street, Columbia, Pennsylvania |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1063954501 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | OA003971 (Pennsylvania) | Secondary |
363AM0700X | Physician Assistant - Medical | MA058449 (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Kelsey Czekai, PA-C 116 S George St Ste 301, York, PA 17401-1443 Ph: (717) 801-4821 | Kelsey Czekai, PA-C 369 Locust Street, First Floor, Columbia, PA 17512 Ph: (717) 342-2577 |
News Archive
Today's headlines include health policy headlines from Capitol Hill and from the insurance markeplace.
The percentage of substance abuse treatment facilities offering nicotine replacement therapy to clients gradually increased by about 6 percentage points from 2006 to 2009, according to a new Spotlight report issued by the Substance Abuse and Mental Health Services Administration released in conjunction with the "Great American Smokeout."
Chimerix, Inc., a biotechnology company developing novel antiviral therapeutics, today announced positive results from CMX001 Study 201, a Phase 2 study evaluating CMX001 for the prevention of cytomegalovirus (CMV) disease in hematopoietic stem cell transplant (HCT) recipients.
Using computer models and laboratory rats, Johns Hopkins researchers have demonstrated that "direct electrical current" can be delivered to nerves preferentially, blocking pain signals while leaving other sensations undisturbed.
In recent years, researchers have been frustrated because there are no tools to identify early stages of osteoarthritis and thus no good way to test therapies for preventing or slowing the disease. Now, three institutions have been awarded $1 million from the Arthritis Foundation to validate the use of new MRI (magnetic resonance imaging) techniques and newly identified biomarkers to solve this vexing problem.
› Verified 4 days ago